{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:58:05Z","timestamp":1781665085425,"version":"3.54.5"},"reference-count":48,"publisher":"Norwegian Medical Association","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"published-print":{"date-parts":[[2011,10,18]]},"DOI":"10.4045\/tidsskr.11.0138","type":"journal-article","created":{"date-parts":[[2011,10,20]],"date-time":"2011-10-20T03:55:45Z","timestamp":1319082945000},"page":"2000-3","source":"Crossref","is-referenced-by-count":7,"title":["Legemiddelinteraksjoner og immunsuppresjon hos organtransplanterte"],"prefix":"10.4045","volume":"131","author":[{"given":"Nils Tore","family":"Vethe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Midtvedt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"\u00c5sberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune","family":"Amundsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stein","family":"Bergan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Wallemacq PE. Therapeutic monitoring of immunosuppressant drugs. Where are we? Clin Chem Lab Med 2004; 42: 1204\u2009\u2013\u200911. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15576284&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1515\/CCLM.2004.242","DOI":"10.1515\/CCLM.2004.242"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. Transplant Proc 2004; 36 (suppl 2): 25S-32S. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15041303&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.transproceed.2004.01.018","DOI":"10.1016\/j.transproceed.2004.01.018"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009; 9: 324\u2009\u2013\u200937. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19390566&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038\/nri2546","DOI":"10.1038\/nri2546"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006; 26: 1730\u2009\u2013\u200944. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17125435&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1592\/phco.26.12.1730","DOI":"10.1592\/phco.26.12.1730"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Cascorbi I. P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol 2011; 201: 261\u2009\u2013\u200983. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21103972&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007\/978-3-642-14541-4_6","DOI":"10.1007\/978-3-642-14541-4_6"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Marchetti S, Mazzanti R, Beijnen JH et al. Concise review: clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 2007; 12: 927\u2009\u2013\u200941. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17766652&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1634\/theoncologist.12-8-927","DOI":"10.1634\/theoncologist.12-8-927"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Liu YT, Hao HP, Liu CX et al. Drugs as CYP3A probes, inducers, and inhibitors. Drug Metab Rev 2007; 39: 699\u2009\u2013\u2009721. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18058330&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1080\/03602530701690374","DOI":"10.1080\/03602530701690374"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41\u2009\u2013\u200957. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10668858&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.2165\/00003088-200038010-00003","DOI":"10.2165\/00003088-200038010-00003"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Martin JE, Daoud AJ, Schroeder TJ et al. The clinical and economic potential of cyclosporin drug interactions. Pharmacoeconomics 1999; 15: 317\u2009\u2013\u200937. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10537952&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.2165\/00019053-199915040-00001","DOI":"10.2165\/00019053-199915040-00001"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Zimmerman JJ. Exposure-response relationships and drug interactions of sirolimus. AAPS J 2004; 6:\u00a0e28. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15760093&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1208\/aapsj060428","DOI":"10.1208\/aapsj060428"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Kandrotas RJ, Slaughter RL, Brass C et al. Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol. Clin Pharmacol Ther 1987; 42: 465\u2009\u2013\u200970. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3311551&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038\/clpt.1987.179","DOI":"10.1038\/clpt.1987.179"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Lebrun-Vignes B, Archer VC, Diquet B et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001; 51: 443\u2009\u2013\u200950. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11422002&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1046\/j.1365-2125.2001.01372.x","DOI":"10.1046\/j.1365-2125.2001.01372.x"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Fost DA, Leung DY, Martin RJ et al. Inhibition of\u00a0methylprednisolone elimination in the presence of clarithromycin therapy. J Allergy Clin Immunol 1999; 103: 1031\u2009\u2013\u20095. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10359882&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/S0091-6749(99)70175-2","DOI":"10.1016\/S0091-6749(99)70175-2"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"LaForce CF, Szefler SJ, Miller MF et al. Inhibition of methylprednisolone elimination in the presence of erythromycin therapy. J Allergy Clin Immunol 1983; 72: 34\u2009\u2013\u20099. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6602160&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/0091-6749(83)90049-0","DOI":"10.1016\/0091-6749(83)90049-0"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"B\u00f6ttiger Y, S\u00e4we J, Brattstr\u00f6m C et al. Pharmacokinetic interaction between single oral doses of\u00a0diltiazem and sirolimus in healthy volunteers. Clin Pharmacol Ther 2001; 69: 32\u2009\u2013\u200940. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11180036&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1067\/mcp.2001.112513","DOI":"10.1067\/mcp.2001.112513"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Jones TE, Morris RG. Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients. Clin Pharmacokinet 2002; 41: 381\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12036394&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.2165\/00003088-200241050-00005","DOI":"10.2165\/00003088-200241050-00005"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Kovarik JM, Beyer D, Bizot MN et al. Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. Br J Clin Pharmacol 2005; 60: 434\u2009\u2013\u20097. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16187976&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1365-2125.2005.02434.x","DOI":"10.1111\/j.1365-2125.2005.02434.x"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Varis T, Backman JT, Kivist\u00f6 KT et al. Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone. Clin Pharmacol Ther 2000; 67: 215\u2009\u2013\u200921. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10741623&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1067\/mcp.2000.104611","DOI":"10.1067\/mcp.2000.104611"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Brandhorst G, Tenderich G, Zittermann A et al. Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor. Ther Drug Monit 2008; 30: 113\u2009\u2013\u20096. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18223473&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097\/FTD.0b013e318161a335","DOI":"10.1097\/FTD.0b013e318161a335"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Zhi J, Moore R, Kanitra L et al. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. J Clin Pharmacol 2002; 42: 1011\u2009\u2013\u20099. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12211217&dopt=Abstract","DOI":"10.1177\/0091270002042009008"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481\u2009\u2013\u2009508. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19218475&dopt=Abstract","DOI":"10.2215\/CJN.04800908"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Venkataramanan R, Zang S, Gayowski T et al. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 2002; 46: 3091\u2009\u2013\u20093. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12183280&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1128\/AAC.46.9.3091-3093.2002","DOI":"10.1128\/AAC.46.9.3091-3093.2002"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Capone D, Tarantino G, Gentile A et al. Effects of\u00a0voriconazole on tacrolimus metabolism in a\u00a0kidney transplant recipient. J Clin Pharm Ther 2010; 35: 121\u2009\u2013\u20094. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20175821&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1365-2710.2009.01070.x","DOI":"10.1111\/j.1365-2710.2009.01070.x"},{"key":"ref=24","doi-asserted-by":"crossref","unstructured":"Kovarik JM, Beyer D, Bizot MN et al. Blood concentrations of everolimus are markedly increased by ketoconazole. J Clin Pharmacol 2005; 45: 514\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15831774&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1177\/0091270005275368","DOI":"10.1177\/0091270005275368"},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"Kovarik JM, Hsu CH, McMahon L et al. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther 2001; 70: 247\u2009\u2013\u200954. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11557912&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1067\/mcp.2001.118022","DOI":"10.1067\/mcp.2001.118022"},{"key":"ref=26","doi-asserted-by":"crossref","unstructured":"Mori T, Aisa Y, Nakazato T et al. Tacrolimus-azithromycin interaction in a recipient of allogeneic bone marrow transplantation. Transpl Int 2005; 18:\u00a0757\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15910307&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1432-2277.2005.00135.x","DOI":"10.1111\/j.1432-2277.2005.00135.x"},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"Midtvedt K, Hartmann A, Foss A et al. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation 2001; 72: 1787\u2009\u2013\u200992. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11740389&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097\/00007890-200112150-00013","DOI":"10.1097\/00007890-200112150-00004"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"Anglicheau D, Pallet N, Rabant M et al. Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int 2006; 70: 1019\u2009\u2013\u200925. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16837925&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038\/sj.ki.5001649","DOI":"10.1038\/sj.ki.5001649"},{"key":"ref=29","doi-asserted-by":"crossref","unstructured":"Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005; 80 (suppl): S181\u2009\u2013\u200990. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16251851&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097\/01.tp.0000186390.10150.66","DOI":"10.1097\/01.tp.0000186390.10150.66"},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"Mandla R, Midtvedt K, Line PD et al. Mycophenolic acid clinical pharmacokinetics influenced by a cyclosporine C2 based immunosuppressive regimen in renal allograft recipients. Transpl Int 2006; 19: 44\u2009\u2013\u200953. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16359376&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1432-2277.2005.00228.x","DOI":"10.1111\/j.1432-2277.2005.00228.x"},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"Picard N, Pr\u00e9maud A, Rousseau A et al. A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. Br J Clin Pharmacol 2006; 62:\u00a0477\u2009\u2013\u200984. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16995869&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1365-2125.2006.02509.x","DOI":"10.1111\/j.1365-2125.2006.02509.x"},{"key":"ref=32","doi-asserted-by":"crossref","unstructured":"Zucker K, Rosen A, Tsaroucha A et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997; 5: 225\u2009\u2013\u200932. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9402690&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/S0966-3274(97)80042-1","DOI":"10.1016\/S0966-3274(97)80042-1"},{"key":"ref=33","doi-asserted-by":"crossref","unstructured":"Doesch AO, Mueller S, Konstandin M et al. Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. Transplant Proc 2010; 42: 4243\u2009\u2013\u20096. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21168674&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.transproceed.2010.09.047","DOI":"10.1016\/j.transproceed.2010.09.047"},{"key":"ref=34","doi-asserted-by":"crossref","unstructured":"Kofler S, Deutsch MA, Bigdeli AK et al. Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. J Heart Lung Transplant 2009; 28: 605\u2009\u2013\u200911. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19481022&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.healun.2009.03.006","DOI":"10.1016\/j.healun.2009.03.006"},{"key":"ref=35","doi-asserted-by":"crossref","unstructured":"Miura M, Satoh S, Inoue K et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit 2008; 30: 46\u2009\u2013\u200951. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18223462&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097\/FTD.0b013e31816337b7","DOI":"10.1097\/FTD.0b013e31816337b7"},{"key":"ref=36","doi-asserted-by":"crossref","unstructured":"Naesens M, Kuypers DR, Streit F et al. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients. Clin Pharmacol Ther 2006; 80: 509\u2009\u2013\u200921. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17112807&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.clpt.2006.08.002","DOI":"10.1016\/j.clpt.2006.08.002"},{"key":"ref=37","doi-asserted-by":"crossref","unstructured":"Kuypers DR, Verleden G, Naesens M et al. Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate-glucuronosyltransferase. Clin Pharmacol Ther 2005; 78: 81\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16003296&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.clpt.2005.03.004","DOI":"10.1016\/j.clpt.2005.03.004"},{"key":"ref=38","doi-asserted-by":"crossref","unstructured":"Annapandian VM, John GT, Mathew BS et al. Pharmacokinetic interaction between sodium valproate and mycophenolate in renal allograft recipients. Transplantation 2009; 88: 1143\u2009\u2013\u20095. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19898213&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097\/TP.0b013e3181bb99ff","DOI":"10.1097\/TP.0b013e3181bb99ff"},{"key":"ref=39","doi-asserted-by":"crossref","unstructured":"Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin\u00a0Pharmacokinet 1998; 34: 429\u2009\u2013\u200955. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9646007&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.2165\/00003088-199834060-00002","DOI":"10.2165\/00003088-199834060-00002"},{"key":"ref=40","doi-asserted-by":"crossref","unstructured":"Pieper AK, Buhle F, Bauer S et al. The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Nephrol Dial Transplant 2004; 19: 2630\u2009\u2013\u20093. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15304561&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1093\/ndt\/gfh446","DOI":"10.1093\/ndt\/gfh446"},{"key":"ref=41","doi-asserted-by":"crossref","unstructured":"Naderer OJ, Dupuis RE, Heinzen EL et al. The influence of norfloxacin and metronidazole on the\u00a0disposition of mycophenolate mofetil. J Clin Pharmacol 2005; 45: 219\u2009\u2013\u200926. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15647415&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1177\/0091270004271555","DOI":"10.1177\/0091270004271555"},{"key":"ref=42","doi-asserted-by":"crossref","unstructured":"Schmidt LE, Rasmussen A, N\u00f8rrelykke MR et al. The effect of selective bowel decontamination on the pharmacokinetics of mycophenolate mofetil in\u00a0liver transplant recipients. Liver Transpl 2001; 7:\u00a0739\u2009\u2013\u200942. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11510021&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1053\/jlts.2001.26365","DOI":"10.1053\/jlts.2001.26365"},{"key":"ref=43","doi-asserted-by":"crossref","unstructured":"Goutelle S, Mialou V, Gouraud A et al. Probable drug interaction between intravenous ciprofloxacin and mycophenolate mofetil in a bone marrow transplant recipient. Pharmacotherapy 2011; 31: 37e-40e. Crossref: http:\/\/dx.doi.org\/10.1592\/phco.31.1.114","DOI":"10.1592\/phco.31.1.114"},{"key":"ref=44","doi-asserted-by":"crossref","unstructured":"Kofler S, Wolf C, Shvets N et al. The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients. J Heart Lung Transplant 2011; 30:\u00a0565\u2009\u2013\u200971. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21256049&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.healun.2010.12.003","DOI":"10.1016\/j.healun.2010.12.003"},{"key":"ref=45","doi-asserted-by":"crossref","unstructured":"Bullingham R, Shah J, Goldblum R et al. Effects of\u00a0food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br J Clin Pharmacol 1996; 41: 513\u2009\u2013\u20096. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8799515&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1046\/j.1365-2125.1996.03636.x","DOI":"10.1046\/j.1365-2125.1996.03636.x"},{"key":"ref=46","doi-asserted-by":"crossref","unstructured":"Rae JM, Johnson MD, Lippman ME et al. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J\u00a0Pharmacol Exp Ther 2001; 299: 849\u2009\u2013\u200957. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11714868&dopt=Abstract","DOI":"10.1016\/S0022-3565(24)29202-8"},{"key":"ref=47","doi-asserted-by":"crossref","unstructured":"Czock D, Keller F, Rasche FM et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005; 44: 61\u2009\u2013\u200998. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15634032&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.2165\/00003088-200544010-00003","DOI":"10.2165\/00003088-200544010-00003"},{"key":"ref=48","doi-asserted-by":"crossref","unstructured":"Bartoszek M, Brenner AM, Szefler SJ. Prednisolone and methylprednisolone kinetics in children. Clin Pharmacol Ther 1987; 42: 424\u2009\u2013\u200932. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3665340&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038\/clpt.1987.173","DOI":"10.1038\/clpt.1987.173"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":[],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:34:36Z","timestamp":1781663676000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2011\/10\/oversiktsartikkel\/legemiddelinteraksjoner-og-immunsuppresjon-hos-organtransplanterte"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,18]]},"references-count":48,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2011,10,18]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.11.0138","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,18]]}}}